Table V.
Association of folate pathway gene expression and clinical features with the risk of relapse to AL.
| Univariate analysis | Multivariate analysis | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Variable (n) | Without relapse n (%) | With relapse n (%) | P-valuea | OR | CI 95% | P-valueb | OR | CI 95% | P-valuec |
| Sex | |||||||||
| Female | 9 | 18 | 1.00 | ||||||
| Male | 9 | 33 | 0.400 | 1.83 | 0.62–5.44 | 0.275 | |||
| Risk by age and leukocytes at diagnosis | |||||||||
| Low-risk | 11 | 15 | 1.00 | ||||||
| High-risk | 7 | 36 | 0.024d | 3.77 | 1.23–11.59 | 0.020d | |||
| Immunophenotype | |||||||||
| Lymphoid-lineage | 14 | 36 | 1.00 | ||||||
| Myeloid-lineage | 4 | 15 | 0.761 | 1.14 | 0.41–5.16 | 0.549 | |||
| RFC1 (61) | |||||||||
| Low-levels | 4 (25.0) | 27 (60.0) | 0.021d | 1.00 | |||||
| High-levels | 12 (75.0) | 18 (40.0) | 0.22 | 0.06–0.80 | 0.021d | 0.23 | 0.06–0.87 | 0.030d | |
| GGH (63) | |||||||||
| Low-levels | 13 (72.2) | 17 (37.8) | 0.024d | 1.00 | |||||
| High-levels | 5 (27.8) | 28 (62.2) | 4.28 | 1.29–14.14 | 0.017d | 6.53 | 1.65–25.83 | 0.008d | |
| FPGS (63) | |||||||||
| Low-levels | 8 (50.0) | 23 (48.9) | 1.00 | 1.00 | |||||
| High-levels | 8 (50.0) | 24 (51.1) | 1.04 | 0.34–3.25 | 0.941 | ||||
| TS (69) | |||||||||
| Low-levels | 15 (83.3) | 21 (41.2) | 0.002d | 1.00 | |||||
| High-levels | 3 (16.7 | 30 (58.8) | 7.14 | 1.84–27.81 | 0.005d | 7.40 | 1.81–30.33 | 0.005d | |
| ATIC (69) | |||||||||
| Low-levels | 6 (33.3) | 29 (56.9) | 0.106 | 1.00 | |||||
| High-levels | 12 (66.7) | 22 (43.1) | 0.38 | 0.12–1.17 | 0.086 | ||||
| MTHFR (59) | |||||||||
| Low-levels | 11 (73.3) | 16 (49.1) | 0.037d | 1.00 | |||||
| High-levels | 4 (26.7) | 28 (50.9) | 4.81 | 1.31–17.64 | 0.018d | 4.50 | 1.18–17.12 | 0.027d | |
| MTHFD1 (60) | |||||||||
| Low-levels | 7 (46.7) | 23 (51.1) | 1.00 | 1.00 | |||||
| High-levels | 8 (53.3) | 22 (48.9) | 0.84 | 0.26–2.69 | 0.766 | ||||
| MTRR (64) | |||||||||
| Low-levels | 7 (43.8) | 27 (56.2) | 0.405 | 1.00 | |||||
| High-levels | 9 (56.2) | 21 (43.8) | 0.60 | 0.19–1.89 | 0.388 | ||||
| MS (64) | |||||||||
| Low-levels | 8 (47.1) | 27 (57.4) | 0.573 | 1.00 | |||||
| High-levels | 9 (52.9) | 20 (42.6) | 0.66 | 0.22–2.01 | 0.462 | ||||
| ABCB1 (69) | |||||||||
| Low-levels | 14 (77.8) | 22 (43.1) | 0.014d | 1.00 | |||||
| High-levels | 4 (22.2) | 29 (56.9) | 4.61 | 1.33–15.97 | 0.016d | 5.13 | 1.38–18.98 | 0.014d | |
| ABCC1 (63) | |||||||||
| Low-levels | 13 (86.7) | 26 (54.2) | 0.033d | 1.00 | |||||
| High-levels | 2 (13.3) | 22 (45.8) | 5.50 | 1.12–27.06 | 0.036d | 4.85 | 0.95–24.74 | 0.050d | |
OR, odds ratio; CI, confidence interval
a
P-value was obtained by the Chi-square test.
b
P-value was obtained by univariate logistic regression analysis, taking reference to female, 1–10 years/<50,000 leukocytes/mm (low-risk), Lymphoid-lineage and Low-levels (RFC1, GGH, FPGS, TS, ATIC, MTHFR, MTHFD1, MTRR, MS, ABCB1 and ABCC1).
c
P-value was obtained by multivariate logistic regression analysis between relapse, risk by age and leukocytes at diagnosis and mRNA expression levels of genes involved in the transport (RFC1, ABCB1 and ABCC1) and metabolism (GGH, TS and MTHFR) of MTX.
d
Significant P<0.05.